VCP and cancer: Several studies reported the development of VCP inhibitors and showed that these compounds induce ER stress and apoptosis in cancer cells.21–23 High-throughput screening of compound libraries from Maybridge Hitfinder Collection and NIH Molecular Libraries Small Molecule Repository yielded in the identification of DBeQ (N2,N4-dibenzylquinazoline-2,4-diamine) as a selective, reversible, ATP-competitive inhibitor of VCP.21 Subsequently, a structure–activity relationship study was performed using DBeQ and N-benzyl-2-(2-flurorophenyl) quinazoline-4-amine 1 as a starting point.